SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Fennec Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmBusiness Wire • 09/04/20
EQUITY ALERT: ROSEN, A LEADING NATIONAL LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Fennec Pharmaceuticals Inc. – FENCBusiness Wire • 09/04/20
FENC CLASS ACTION NOTICE: The Law Offices of Frank R. Cruz Files a Securities Fraud Class Action Lawsuit Against Fennec Pharmaceuticals Inc.Business Wire • 09/04/20
FENC CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Fennec Pharmaceuticals Inc.Business Wire • 09/03/20
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Fennec Pharmaceuticals Inc.Business Wire • 08/20/20
The Law Offices of Frank R. Cruz Continues Its Investigation of Fennec Pharmaceuticals Inc.Business Wire • 08/20/20
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Fennec Pharmaceuticals Inc. (FENC) on Behalf of InvestorsBusiness Wire • 08/20/20
INVESTOR ALERT: Kirby McInerney LLP Continues Investigation of Shareholder Claims Against Fennec Pharmaceuticals Inc.Business Wire • 08/19/20
FENNEC ALERT: Bragar Eagel & Squire, P.C. is Investigating Fennec Pharmaceuticals, Inc.Business Wire • 08/18/20
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Fennec Pharmaceuticals Inc. and Encourages Investors with Losses of $100,000 to Contact the FirmBusiness Wire • 08/18/20
The Law Offices of Frank R. Cruz Announces Investigation of Fennec Pharmaceuticals Inc.Business Wire • 08/17/20
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Fennec Pharmaceuticals Inc.Business Wire • 08/17/20
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Fennec Pharmaceuticals Inc. and Encourages Investors with Losses of $100,000 to Contact the FirmBusiness Wire • 08/17/20
EQUITY ALERT: ROSEN, A LEADING AND RANKED FIRM, Announces Investigation of Securities Claims Against Fennec Pharmaceuticals Inc. – FENCBusiness Wire • 08/17/20
Ultimate Valuation Inflection Point Rapidly Approaching For Fennec Pharmaceuticals (Pedmark PDUFA Date August 10, 2020)Seeking Alpha • 08/06/20
Fennec Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Business UpdateGlobeNewsWire • 08/05/20
Fennec Pharmaceuticals Announces First Quarter 2020 Financial Results and Provides Business UpdateGlobeNewsWire • 05/14/20
Fennec Announces Exercise and Closing of Underwriters’ Option to Purchase Additional SharesGlobeNewsWire • 05/08/20
Fennec Pharmaceuticals Announces FDA Filing Acceptance and Priority Review of New Drug Application for PEDMARK™GlobeNewsWire • 04/13/20
Fennec Pharmaceuticals Receives European Medicines Agency Validation for Marketing Authorization Application for Sodium ThiosulfateGlobeNewsWire • 02/28/20
Fennec Pharmaceuticals: Market Fatigue Due To A Lack Of Catalysts Has Created A Mispricing - Behind The IdeaSeeking Alpha • 02/19/20